VTRS - Viatris Q1 earnings in focus amid plans to divest some European assets

2023-05-05 11:24:04 ET

Viatris ( NASDAQ: VTRS ) is scheduled to announce Q1 earnings results on Monday, May 8th, before market open.

The consensus EPS Estimate is $0.70 (+112.1% Y/Y) and the consensus Revenue Estimate is $3.81B (-9.1% Y/Y).

Over the last 1 year, VTRS has beaten EPS estimates 50% of the time and has beaten revenue estimates 50% of the time.

Over the last 3 months, EPS estimates have seen 0 upward revisions and 4 downward. Revenue estimates have seen 0 upward revisions and 3 downward.

The company's stock dipped -2.69% on Feb. 27 after mixed Q4 results . Viatris saw a one-off gain of ~$1.8B related to its biosimilar divestiture which led to $1.0B GAAP net income . However, sales fell -10.6% Y/Y and also missed estimates.

Viatris has been mulling the sale of its European consumer-health assets and in March the the company asked potential buyers to resubmit their offers. The company was originally trying to fetch €3B and was asking for offers for the whole unit, but later reconsidered selling parts of the portfolio and also exclude erectile-dysfunction drug Viagra.

During the quarter, Viatris also began a settlement with Merck over a patent dispute for diabetes drugs Januvia and Janumet.

Other News :

Viatris was among the three companies to sign an agreement with the United Nations-backed Medicines Patent Pool to produce generic versions of ViiV Healthcare's long-acting HIV prevention medicine for low income countries.

The company withdrew an application for generic HIV therapy Raltegravir Viatris in the EU.

More on the company from SA contributors:

Viatris - Time To Cut This Business Some Slack?

Viatris: The Value And The Value Trap

For further details see: